Hemodynamic effects of levosimendan in addition to dobutamine infusion in patients with advanced heart failure intractable to dobutamine infusion alone  by Papazoglou, Panagiotis et al.
206A ABSTRACTS - Cardiac Function and Heart Failure JACC 
Further, lipid lowering may not be as beneficial in advanced disease. We compared sur- 
vival associated with statin therapy in CAD pts with and without LVD. 
Methods: A cohort of 2,202 non-LVD pts and 364 LVD pts with angiographically defined 
CAD (270% stenosis), were studied from the registry of the Intermountain Heart Collab- 
orative Study at LDS Hospital. Risk factors and clinical data, including statin prescription 
at discharge, were recorded at baseline. Pts were followed for 3.0+1.9 years (maximum 
7.7 years) to determine the incidence of mortality. Cox regression and Kaplan-Meier esti- 
mates were used to model survival in both groups. 
Results: Patient age (63+12 years) and gender (34% female) did not differ between the 
groups. Statins were prescribed at discharge for 28% of non-LVD and 26% of LVD pts 
(p=NS). Among non-LVD patients, mortality was 6.6% for statin prescribed pts and 
12.7% for those not prescribed statins (p=O.O05 by log-rank); among LVD pts, mortality 
was 16.0% when prescribed statins and 32.6% when no statin was prescribed (p=O.O17 
by log-rank). After adjustment for covariables. these associations remained for non-LVD 
pts (hazard ratio [HR]= 0.66,95% Cl= 0.47-0.93), and LVD pts (HiX0.57, Cl= 0.33-0.99). 
No interaction was found between statin prescription and EF for moriality (p-interac- 
tiow0.71). 
Conclusion: Proportionate benefit from statin prescription was similar in LVD and non- 
LVD groups, but absolute benefit was greater in LVD pts (16% vs. 6% absolute mortality 
reduction). These results demonstrate the benefit of statin discharge prescription, 
regardless of degree of LVD and emphasize current underutilization, particularly in those 
with LVD. 
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Conclusion: The addition of levosimendan had a sustained-therapeutic effect in clini- 
cally unstable patients with CHF refractory to continuous dobutamine and furosemide 
infusions. This regimen could be used as a bridge to left ventricular assist device implan- 
tation or heart transplantation. 
1184-79 Acute Intravenous Ranolazine Improves Lefl Ventricular 
Function in Dogs With Heart Failure: A Dose Escalation 
Study 
Hideaki Morita, George Suzuki, Margaret P. Chandler, William C. Stanley, Brent K. 
Blackbum. Hani N. Sabbah, Henry Ford Health System, Detroit, MI. Case Western 
Reserve University, Cleveland, OH 
Background: To explore the use of intravenous (iv) ranolazine. a partial fatty acid oxida- 
tion inhibitor, as acute therapy for heart failure (HF), we determined the effects of up-titra- 
tion and reversibility of ranolazine in 6 dogs with microembolizations-induced HF. 
Methods: Ranolazine was given as 0.05 mg/kg bolus followed by iv infusion at 0.1, 0.3, 
1.0 and 3.0 mgkglhr each for 1 hour. Heart rate (HR), peak left ventricular (LV) systolic 
pressure (LVSP). stroke volume (SV), LV end-diastolic volume (EDV), LV end-systolic 
volume (ESV). LV ejection fraction (EF) and ranolazine plasma concentration (RANc) 
were measured at baseline and at the end of each dose. Results: The results are shown 
in the table. Ranolazine decreased ESV without affecting EDV. thus increasing EF at all 
doses in a dose and RANc deoendent manner. The increase in EF olateaued at doses 
X.3 mgikglhr, suggesting a half maximal response at -0.1 mg/kg/hr at RANc of 67+11 
no/ml. Ranolazine had nominal effects to reduce HR at doses >0.3 ma/ka/hr and LVSP at 
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1184-77 Utilization of ACE-I and B-blocker Therapy in Managed 
Care Patients With Heart Failure: NC ACE Project 
David C. Gaff. Carfa A. Sueta, David W. Brown, Jill McArdle, Sharon Peacock, Alain 
Bertoni, Wake Forest University School of Medicine, Winston-Salem, NC, Medical 
Review of North Carolina, Gary, NC 
Background: Heart failure (HF) results in substantial morbidity and mortality in the US. 
Despite evidence-based guidelines recommending proven therapies, translation into clin- 
ical practice is suboptimal. The goal of the North Carolina Achieving Cardiac Excellence 
(NC ACE) Project is to increase the utilization of angiotensin converting enzyme inhibitor 
(ACE-l) and @blocker therapies in patients with HF. The purpose of this study is to com- 
pare the management of Medicare and Medicaid patients with HF enrolled in managed 
care. 
Methods: Data were abstracted from outpatient medical records for 971 Medicare (3 
managed care plans) and 654 Medicaid (2 plans) patients treated for HF during 2000. 
Patients receiving dialysis were excluded. 
Results: Compared to Medicaid patients, Medicare patients were older (76i3 vs. 59*14 
years), more likely to be white (64 vs. 47%), and men (50 vs. 30%). More than 80% of 
Medicare (n=795) and Medicaid (n=526) patients had documentation of a quantitative or 
qualitative assessment of left ventricular function (LVF). Left ventricular systolic dysfunc- 
tion (LVSD) was present in 37% (n=297) of Medicare patients and 37% (n=197) of Med- 
icaid patients. 
Indicator Medicare Medicaid 
LVF Assessment 849 (67%) 573 (63%) 
ACE-I in LVSD 215 (72%) 147 (75%) 
ACE-l Intolerance 42 (14%) 23 (12%) 
bblocker in LVSD 144 (46%) 96 (43%) 
eblocker Intolerance 34 (12%) 25 (13%) 
Conclusion: Assessment and treatment of HF appears similar in Medicare and Medicaid 
managed care patients. Although not optimal, these rates are substantially higher than 
previously reported. Opportunities for increasing appropriate use of &blockers should be 
prioritized in these populations. 
1184-78 Hemodynamic Effects of Levosimendan in Addition to 
Dobutamine Infusion in Patients With Advanced Heart 
Failure Intractable to Dobutamine Infusion Alone 
Panaqiotis Pavazoqlou, Maria Anastasiou-Nana, Eleftheria Tsagalou, John Terrovitis. 
Elias Tsolakis. Argirios Dalianis, George Alexopoulos. John Kanakakis, Konstantinos 
Chrfstodoulou, John N. Nanas, University of Athens, Athens, Greece 
Background: Levosimendan is a new calcium-sensitizing agent with positive inotropic 
and vasodilatory effects. 
Purpose: This study measured the magnitude and duration of the hemodynamic 
response to an infusion of levosimendan In clinically unstable patients with advanced 
congestive heart failure (CHF) pretreated with dobutamine and furosemide. 
Methods: In thirteen patients with advanced CHF. 48-77 years of age, in NYHA func- 
tional class IV, previously treated with intermittent dobutamine infusions, and hospital- 
ized for clinical instability despite continuous dobutamine. lOpg/kg/min. and furosemide, 
10 mglh, infuslons, a continuous infusion of levosimendan, in a bolus of 6 kgikg, followed 
by a 0.2 W/kg/min infusion for 24 h. was added. The patients were followed for 7 days, 
including serial right-heart catheterizations. The effect on Systolic Blood Pressure (SBP), 
Cardiac Index (Cl), Pulmonary Capillary Wedge Pressure (PCWP), Right Atrial Pressure 
(RA) and Systemic Vascular Resistance (SVR), before and at 12 hours, 24 hours and 1 
week after levosimendan administration, was recorded. 
Results: The results are summarized in the Table 
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a dose of 3.0 mglkglhr. The effect of ranolazine (0.05 mglkg bolus + 0.3 mg/kg/hr for 1 
hr) declined after stopping infusion in proportion to RANc. Conclusions: Intravenous 
ranolazine improves LV function in dogs with chronic HF in a reversible, dose and con- 
centration dependent manner with little or no impact on HR and LVSP. 
RanolazineDose (mglkglhr) 
Baseline 0.1 0.3 1 .o 3.0 
HR (beats/min) 83+4 80_+6 75_+5’ 74+5 73 i 5’A 
LVSP (mmHg) 9623 102~4 9723 9423 89 _+4’” 
SV (ml) 19+1 23_+1’ 25_+1’” 2621.” 26_+1’” 
EDV (ml) 6624 6623 6524 66+3 6524 
ESV (ml) 4724 43_+4* 41_+3’” 39+3^” 3923’” 
EF (%) 30~2 36_+2’ 36 22’” 33 + 3’” 33 -+ 3.” 
RANc (ng/ml) 0 67i4 106+94 557 i a7 1259_+1354 
*=PcO.O5 vs. Baseline; “=PcO.O5vs. 0.1 mglkglhr 
1184-80 Effect of the Angiotensin Converting Enzyme Inhibitor 
Trandolapril on Functional Status and Furosemide 
Consumption in Patients With Reduced Left Ventricular 
Function After Myocardial Infarction 
Jawdat Abdulla, Lars Kober, Christian Tarp-Pedersen, Gentofte University Hospital of 
Copenhagen, Copenhagen, Denmark 
Background: lnformatlon on the direct benefit of angiotensin converting enzyme inhibi- 
tors on symptoms are scarce and in contrast to the overwhelming amount of information 
on survival. Effect of the use of concommitant diuretic therapy on symptoms has been 
also questioned. Therefore we studied development of New York Heart Association 
(NYHA) classification and use of furosemide in the Trandolapril Cardiac Evaluation Study 
(TRACE). 
Methods: In TRACE 1749 consecutive patients with left ventricular systokc dysfunction 
after myocardial infarction (MI) were randomized to either placebo or trandolapril. The 
patients were assessed for changes in NYHA classes and use of furosemide every 3 
months and were followed up 2-4 years. 
Results: There were no differences in baseline characteristics between the two treatment 
groups. The majority of the patients were in NYHA classes II and I. Both placebo and 
trandolapril groups showed equal improvement in NYHA classes without any significant 
differences (P> 0.05, figure). This result was also found in patients with NYHA class II or 
greater at the time of randomization. Trandolapril resulted in a mild but significant reduc- 
tion of the use of furosemide with a mean reduction of 12 mg/day overall during follow up 
(pcO.001, figure). 
Conclusion: Despite a significant reduction in mortality, trandolapril did not improve 
